New hepatitis drug could be 'transformational': CEO By: CNBC.com News July 28, 2014 at 19:00 PM EDT The potential market for a promising new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says. Read More >> Related Stocks: Gilead Sciences